新型抗心绞痛药
涉及使用螯合疗法治疗心绞痛 (EDTA) 的研究尚未提供充分的证据支持其使用。[179]Knudtson ML, Wyse DG, Galbraith PD, et al; Program to Assess Alternative Treatment Strategies to Achieve Cardiac Health (PATCH) Investigators. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA. 2002 Jan 23-30;287(4):481-6.https://jamanetwork.com/journals/jama/fullarticle/321724http://www.ncbi.nlm.nih.gov/pubmed/11798370?tool=bestpractice.com[180]Lamas GA, Goertz C, Boineau R, et al; TACT Investigators. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013 Mar 27;309(12):1241-50.https://jamanetwork.com/journals/jama/fullarticle/1672238http://www.ncbi.nlm.nih.gov/pubmed/23532240?tool=bestpractice.com 在小型 COSIRA 试验中，已经证明冠状窦减径器 (coronary-sinus-reducing device) 有一定应用前景，能够改善不适合血运重建的难治性心绞痛患者的症状和生活质量。[181]Verheye S, Jolicoeur EM, Behan MW, et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015 Feb 5;372(6):519-27.https://www.nejm.org/doi/full/10.1056/NEJMoa1402556http://www.ncbi.nlm.nih.gov/pubmed/25651246?tool=bestpractice.com 人们对使用低剂量直接口服抗凝剂联合抗血小板药物治疗也表现出兴趣；但是，在血管不良事件的降低中，更多地似乎是由卒中发生率降低所引起，而非心肌梗死发生率的降低，并且该疗法的出血风险有所增加。[182]Connolly SJ, Eikelboom JW, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):205-18.http://www.ncbi.nlm.nih.gov/pubmed/29132879?tool=bestpractice.com
